BEAM
HealthcareBeam Therapeutics Inc. · Biotechnology · $3B
What is Beam Therapeutics Inc.?
Beam Therapeutics is a Cambridge-based biotechnology company pioneering base editing — a precise approach to genetic medicine. Founded in 2020, it is developing treatments for serious blood disorders, immune diseases, and rare metabolic conditions.
Beam Therapeutics develops precision genetic medicines using proprietary base editing technology, which enables targeted changes to DNA without cutting the double strand. The company generates revenue primarily through collaboration agreements and licensing deals with partners including Pfizer, Apellis Pharmaceuticals, and Verve Therapeutics. Its pipeline spans sickle cell disease, beta thalassemia, rare liver disorders, T-cell leukemia, and ocular diseases — all areas with significant unmet medical need.
Beam Therapeutics was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.
- BEAM-101: base editing therapy for sickle cell disease and beta thalassemia
- BEAM-102: alternative base editing approach targeting sickle cell disease
- BEAM-201: allogeneic CAR-T cell therapy for relapsed T-cell leukemia
- BEAM-301: liver-targeted therapy for Glycogen Storage Disease Type Ia
- Collaborative research programs in alpha-1 antitrypsin deficiency and ocular diseases
Is BEAM a Good Stock to Buy?
UQS Score rates BEAM as Below Average overall, reflecting the realities of early-stage biotech investing.
The Growth and Risk pillars are among the brighter spots in BEAM's profile. A diversified pipeline across multiple disease areas, combined with high-profile collaboration agreements, supports a meaningful growth narrative. The Risk pillar rating suggests the company's financial structure is not at the extreme end of vulnerability relative to peers.
The Quality pillar is rated Weak, consistent with a pre-revenue biotech that depends on partnerships and capital raises. Valuation is rated Elevated, meaning the market is pricing in considerable future success.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does BEAM pay dividends?
No — Beam Therapeutics Inc. does not currently pay a dividend.
Beam Therapeutics does not pay a dividend, which is typical for clinical-stage biotechnology companies. Available capital is directed toward research, clinical trials, and pipeline development rather than shareholder distributions. Investors in BEAM are generally seeking long-term value from successful drug approvals rather than income.
When does BEAM report earnings?
Beam Therapeutics reports financial results on a quarterly cadence, standard for US-listed public companies.
As a clinical-stage company, Beam's quarterly results are shaped by collaboration revenue, operating expenses tied to R&D, and cash runway updates rather than product sales. Pipeline milestones and partnership announcements tend to move the stock more than headline earnings figures.
For the most recent quarter's results and management commentary, visit Beam Therapeutics' investor relations page directly.
BEAM Price History
-60.8% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Beam Therapeutics Inc.?
Based on Beam Therapeutics Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
BEAM Long-term Outlook
Beam's fundamental outlook is shaped by the interplay of its Good Growth profile and Elevated Valuation. The pipeline spans multiple disease areas with large patient populations, and existing collaboration agreements with established pharmaceutical companies provide both validation and non-dilutive funding. However, clinical-stage biotech carries binary risk — trial outcomes can sharply reset expectations. The Elevated Valuation label signals that a significant amount of future success is already reflected in the current price.
Growth drivers
- Advancement of base editing candidates through clinical trials across blood and rare disease indications
- Expansion of collaboration revenue through existing and potential new licensing agreements
- Potential regulatory milestones in sickle cell disease, a high-priority therapeutic area
Key risks
- Clinical trial failure or delays in any lead program could materially reset the growth narrative
- Elevated Valuation leaves limited margin of safety if pipeline progress disappoints
- Ongoing capital requirements typical of pre-revenue biotech may lead to dilutive financing
BEAM vs Peers
Beam Therapeutics operates in a competitive rare disease and genetic medicine landscape alongside several focused biotechnology peers.
Catalyst focuses on commercialized rare neuromuscular disease therapies, giving it an approved-product revenue base that Beam currently lacks.
Kiniksa targets rare inflammatory and cardiovascular diseases with a pipeline oriented toward immune-mediated conditions rather than genetic editing.
Denali specializes in neurodegenerative diseases using its transport vehicle platform, competing for investor attention in the precision medicine space.
Frequently Asked Questions
What does Beam Therapeutics do?
Beam Therapeutics develops precision genetic medicines using base editing technology. Unlike traditional gene editing, base editing makes targeted single-letter changes to DNA without breaking the double strand. The company's pipeline targets serious conditions including sickle cell disease, beta thalassemia, rare liver disorders, and certain blood cancers.
Does BEAM pay dividends?
No, Beam Therapeutics does not pay a dividend. As a clinical-stage biotech, the company reinvests all available capital into research and development. Dividend payments are not typical for companies at this stage of development.
When does BEAM report earnings?
Beam Therapeutics follows a standard quarterly reporting schedule. Because it is pre-revenue from product sales, investors typically focus on pipeline updates, cash runway, and collaboration milestones rather than traditional earnings metrics. Check Beam's investor relations page for the latest schedule.
Is BEAM a good stock to buy?
UQS Score rates BEAM as Below Average overall. The Growth and Risk pillars show relative strength, but the Quality pillar is Weak and Valuation is Elevated. Whether it fits a portfolio depends on an investor's risk tolerance and time horizon. The full pillar breakdown is available to UQS Pro members.
Is BEAM overvalued?
UQS Score's Valuation pillar for BEAM is rated Elevated, suggesting the current price reflects a high degree of anticipated future success. For a clinical-stage company without product revenue, valuation is driven largely by pipeline potential and market sentiment around gene editing.
How does BEAM compare to its competitors?
Compared to peers like Catalyst Pharmaceuticals and Kiniksa, Beam is at an earlier commercial stage but is pursuing a differentiated base editing platform. Denali Therapeutics shares a similar profile as a platform-driven, pre-commercial biotech. Each company targets different disease areas and carries distinct risk profiles.
What is BEAM's market cap bracket?
Beam Therapeutics is classified as a mid-cap company. This places it above micro- and small-cap biotechs in terms of market size, though it remains significantly smaller than large-cap pharmaceutical companies with established product portfolios.
Who founded Beam Therapeutics?
Beam Therapeutics was founded by a team of scientists with deep expertise in gene editing, including David Liu, a leading researcher in base editing technology at the Broad Institute. The company was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.
Is BEAM a long-term quality investment?
As a long-term quality indicator, UQS Score currently rates BEAM as Below Average, with a Weak Quality pillar reflecting its pre-revenue status. Long-term quality potential depends heavily on clinical trial outcomes and the company's ability to translate its base editing platform into approved therapies.
What is the main competitive advantage of Beam Therapeutics?
Beam's core differentiation is its proprietary base editing platform, which allows precise single-nucleotide changes to DNA without double-strand breaks. This approach may offer safety and precision advantages over earlier gene editing methods. The platform is validated in part by collaborations with Pfizer and other established partners.
What sector does BEAM belong to?
Beam Therapeutics operates in the Healthcare sector, specifically within biotechnology. It focuses on genetic medicines — a sub-segment attracting significant research investment and regulatory attention as base editing and related technologies mature toward clinical use.
Unlock Full BEAM Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access full financial metrics and quality indicators
- ✓Compare BEAM against sector peers on every pillar
- ✓Track pipeline-stage risk and valuation context
- ✓Get the complete analyst-style breakdown in one place
Pro Analysis
BEAM — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 14, 2026 | 34.5 | 3.3 | 43.0 | 62.4 | 69.6 | 0.0 | +2.0 |
| May 11, 2026 | 32.5 | 3.3 | 43.0 | 62.4 | 56.4 | 0.0 | +0.8 |
| May 10, 2026 | 31.7 | 0.0 | 43.0 | 62.4 | 56.4 | 0.0 | -0.8 |
| May 8, 2026 | 32.5 | 3.3 | 43.0 | 62.4 | 56.4 | 0.0 | -2.8 |
| Apr 2, 2026 | 35.3 | 3.3 | 43.0 | 62.4 | 75.2 | 0.0 | — |
BEAM — Pillar Breakdown
Quality
— 3.3/100 (25%)Beam Therapeutics Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 62.4/100 (20%)Beam Therapeutics Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 69.6/100 (15%)Beam Therapeutics Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Beam Therapeutics Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 43/100 (25%)Beam Therapeutics Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for BEAM.
Score Composition
Financial Data
More Stock Analysis
How is the BEAM UQS Score Calculated?
The UQS (Unified Quality Score) for Beam Therapeutics Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Beam Therapeutics Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Beam Therapeutics Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.